vincristine

Summary

Summary: Antitumor alkaloid isolated from Vinca Rosea. (Merck, 11th ed.)

Top Publications

  1. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
  2. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
  3. ncbi Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
  4. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
  5. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
  6. ncbi MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest
    Yanmin Xu
    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China
    Cancer Lett 310:160-9. 2011
  7. ncbi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
  8. ncbi Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell
    Min Bin Chen
    Department of Medical Oncology, Kunshan First People s Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu Province, China
    J Cell Physiol 226:1915-25. 2011
  9. ncbi Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    Francesco D'Amore
    Dept Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 30:3093-9. 2012
  10. ncbi Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010

Detail Information

Publications334 found, 100 shown here

  1. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)...
  2. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
    ..of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma.
  3. ncbi Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
    Martin J van den Bent
    Neuro Oncology Unit, Erasmus MC Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, The Netherlands
    J Clin Oncol 31:344-50. 2013
    ..We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiotherapy (RT).
  4. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    ..lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
  5. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
    ..DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs...
  6. ncbi MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest
    Yanmin Xu
    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China
    Cancer Lett 310:160-9. 2011
    ..restoration of miR-122 in HCC cells could render cells sensitive to chemotherapeutic agents adriamycin (ADM) or vincristine (VCR)...
  7. ncbi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma...
  8. ncbi Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell
    Min Bin Chen
    Department of Medical Oncology, Kunshan First People s Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu Province, China
    J Cell Physiol 226:1915-25. 2011
    The molecular basis for induction of apoptosis in melanoma cells by vincristine remains unknown. Here we tested the potential involvement of AMP-activated protein kinase (AMPK) in this process...
  9. ncbi Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    Francesco D'Amore
    Dept Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 30:3093-9. 2012
    ..This is the final report, with a 5-year median follow-up, of the NLG-T-01 study...
  10. ncbi Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010
    To compare efficacy and safety of bortezomib plus dexamethasone and vincristine plus doxorubicin plus dexamethasone (VAD) as induction before stem-cell transplantation in previously untreated myeloma.
  11. pmc Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 116:2040-5. 2010
    We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma ..
  12. ncbi Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
    Sarah J L Flatters
    Anaesthesia Research Unit, McIntyre Building, Room 1213, McGill University, 3655 Promenade Sir William Osler, Montreal, QC, Canada H3G 1Y6
    Pain 109:150-61. 2004
    ..Ethosuximide (i.p. 300 mg/kg) also reversed paclitaxel-induced cold allodynia and vincristine-induced mechanical allodynia/hyperalgesia...
  13. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined...
  14. ncbi Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    Robert Marcus
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    J Clin Oncol 26:4579-86. 2008
    ..with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic ..
  15. ncbi Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line
    Zengfu Xue
    State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital of Digestive Diseases, Xi an 710032, China
    J Cell Biochem 113:302-12. 2012
    ..However, there has been no direct observation of the properties of gastric CSCs in vitro. Here we describe a vincristine (VCR)-preconditioning approach to obtain cancer stem-like cells (CSLCs) from the gastric cancer cell line ..
  16. ncbi Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
    Min H Kang
    Developmental Therapeutics Program, Childrens Hospital Los Angeles and University of Southern California Institute for Pediatric Clinical Research, Los Angeles, CA 90027, USA
    Blood 110:2057-66. 2007
    ..We evaluated the cytotoxicity of ABT-737 in combination with vincristine, dexamethasone, and L-asparaginase (VXL) in 7 ALL cell lines...
  17. ncbi Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
    Nalan Akyurek
    Department of Pathology, Medical Faculty, Gazi University, Ankara, Turkey
    Cancer 118:4173-83. 2012
    ..The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.
  18. ncbi Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma
    Michael Brada
    The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 28:4601-8. 2010
    ..We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.
  19. ncbi Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
    Michael Pfreundschuh
    Saarland University Medical School, Homburg Saar, Germany
    Blood 104:626-33. 2004
    The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas...
  20. ncbi Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study
    M A Rodriguez
    Lymphoma Myeloma Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:3475-82. 2009
    Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has targeted, increased, and sustained delivery of vincristine to tumor tissues...
  21. ncbi Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response
    Alexandra M Levine
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 22:2662-70. 2004
    ..Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL)...
  22. ncbi A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
    William W L Choi
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Clin Cancer Res 15:5494-502. 2009
    ..Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm...
  23. ncbi Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Norbert Schmitz
    Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany
    Blood 116:3418-25. 2010
    ..Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP)...
  24. ncbi Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor
    Ana S Martins
    Laboratory 20 Molecular Pathology, Centro de Investigación del Cáncer Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca Consejo Superior de Investigaciones Cientificas, Salamanca, Spain
    Clin Cancer Res 12:3532-40. 2006
    ..We recently showed the cytostatic role of imatinib, an inhibitor of the SCF-KIT loop, on Ewing tumor cells, and in this study, we intend to analyze the inhibition of the insulin-like growth factor I receptor (IGF1R) loop...
  25. ncbi Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine
    Line Groth-Pedersen
    Apoptosis Department and Centre for Genotoxic Stress Research, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Cancer Res 67:2217-25. 2007
    b>Vincristine is a microtubule-destabilizing antimitotic drug that has been used in cancer therapy for over 40 years. However, the knowledge on vincristine-induced cell death pathways is still sparse...
  26. ncbi Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide
    C Arndt
    Department of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1894-901. 2004
    To evaluate the spectrum of and determine the risk factors for the development of liver toxicity (hepatopathy) after therapy with vincristine, dactinomycin, and cyclophosphamide (VAC) for rhabdomyosarcoma in children and adolescents.
  27. pmc Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models
    M S Webb
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Br J Cancer 72:896-904. 1995
    This study reports on the development of a liposomal formulation of vincristine with significantly enhanced stability and biological properties...
  28. ncbi High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
    Giuseppe Maria Milano
    Division of Pediatric Oncology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy
    Cancer 106:1838-45. 2006
    ..The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT.
  29. ncbi Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model
    Man Yi Wong
    Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
    Nanomedicine 7:834-40. 2011
    ..This study sought to develop a liposome formulation containing a synergistic combination of vincristine and quercetin, with prolonged drug circulation times and coordinated drug release in vivo, to develop effective ..
  30. ncbi Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin
    Michael J W Johnston
    Department of Biochemistry and Molecular Biology, University of British Columbia, 2146 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3
    Biochim Biophys Acta 1768:1121-7. 2007
    ..In the case of liposomal formulations of vincristine, for example, the half-times for drug release (T(1/2)) were approximately 3-fold longer for DHSM/Chol LN as ..
  31. pmc Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
    R Parameswaran
    Section of Molecular Carcinogenesis, Division of Hematology Oncology and The Saban Research Institute of Childrens Hospital of Los Angeles, Los Angeles, CA 90027, USA
    Leukemia 25:1314-23. 2011
    ..Similarly, immunocompromised mice transplanted with human ALL cells and treated with vincristine and AMD11070 had few circulating leukemic cells, normal spleens and reduced human CD19+ cells in the BM at the ..
  32. ncbi Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach
    Andrew S Moore
    Queensland Children s Cancer Centre, Royal Children s and Mater Children s Hospitals, Australia
    J Paediatr Child Health 47:875-82. 2011
    b>Vincristine is a key component of many childhood cancer treatment regimens. Pharmacodynamic parameters such as clinical efficacy and toxicity may be influenced by polymorphisms of CYP3A.
  33. pmc Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia
    Sindhu Ramchandren
    Department of Neurology, Detroit Medical Center, Wayne State University, Detroit, MI 48201, USA
    J Peripher Nerv Syst 14:184-9. 2009
    ..Standard ALL treatment includes multiple administrations of the chemotherapeutic drug vincristine, which is a known neurotoxic agent...
  34. ncbi Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1
    Zhenzhen Zhan
    Department of Immunology Anhui Medical University Hefei, Anhui China
    Autophagy 8:109-21. 2012
    ..the extracellular space protects gastric cancer cells from apoptosis induced by the microtubule-targeting drug vincristine through transcriptional upregulation of Mcl-1...
  35. ncbi Preparation, characterization, and biological analysis of liposomal formulations of vincristine
    Dawn N Waterhouse
    Department of Advanced Therapeutics, British Columbia Cancer Agency, British Columbia, Canada
    Methods Enzymol 391:40-57. 2005
    b>Vincristine is a dimeric Catharanthus alkaloid derived from the Madagascan periwinkle that acts by binding to tubulin and blocking metaphase in actively dividing cells...
  36. ncbi The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse
    Richard B Lock
    Children s Cancer Institute Australia for Medical Research School of Paediatrics, University of New South Wales, Australia
    Blood 99:4100-8. 2002
    ..96; P =.002), but not diagnosis (r = 0.38; P =.40). In contrast, the in vivo responses of 6 xenografts to vincristine showed a direct correlation (r = 0.96; P =...
  37. ncbi Vincristine: Can its therapeutic index be enhanced?
    Andrew Moore
    Section of Paediatric Oncology, The Institute of Cancer Research, Sutton, United Kingdom
    Pediatr Blood Cancer 53:1180-7. 2009
    b>Vincristine is one of the most widely used and more effective drugs in paediatric oncology...
  38. pmc Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)
    Susan J Zunino
    United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, 430 West Health Sciences Drive, Davis, CA 95616, United States
    Cancer Lett 296:49-54. 2010
    ..Once engraftment was observed, mice were injected intraperitoneally with phosphate-buffered saline (PBS), or vincristine (0.5mg/kg body weight) three times per week for 4weeks (n=8 per group)...
  39. ncbi CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany
    Lancet Oncol 12:1013-22. 2011
    ..first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma...
  40. ncbi Therapies for peripheral T-cell lymphomas
    Kerry J Savage
    BC Cancer Agency, Vancouver, BC
    Hematology Am Soc Hematol Educ Program 2011:515-24. 2011
    ..The standard therapy for PTCLs is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines...
  41. ncbi Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition
    Guixia Ling
    School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China
    J Control Release 148:241-8. 2010
    To improve the encapsulation efficiency and oral bioavailability of vincristine sulfate (VCR), novel self-assembled dextran sulphate-PLGA hybrid nanoparticles (DPNs) were successfully developed using self-assembly and nanoprecipitation ..
  42. pmc Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro
    Undurti N Das
    Jawaharlal Nehru Technological University, Kakinada 533 003, India
    Lipids Health Dis 10:159. 2011
    ..it was observed that dihomo-gamma-linolenic acid (DGLA) and AA, EPA and DHA have cytotoxic action on both vincristine-sensitive (KB-3-1) and resistant (KB-Ch(R)-8-5) cancer cells in vitro that appeared to be a free-radical ..
  43. ncbi Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:1492-9. 2002
    ..The authors investigated the feasibility and efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive chemotherapy regimen, in patients with AIDS-..
  44. ncbi Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines
    Luigi Rigacci
    Department of Hematology, Careggi Hospital and University of Florence, Italy
    Hematol Oncol 25:198-203. 2007
    ..the efficacy and safety of the combination of non-pegylated liposome-encapsulated doxorubicin (Myocet(R)) with cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) in patients with aggressive non-Hodgkin's B-cell lymphomas.
  45. ncbi Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial
    S Luminari
    Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
    Ann Oncol 21:1492-9. 2010
    ..To evaluate the activity and safety of nonpegylated liposomal doxorubicin (Myocet) when substituted for doxorubicin in the R-CHOP regimen (R-COMP)...
  46. ncbi Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience
    Fariba Navid
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 106:1846-56. 2006
    Intensified chemotherapy may improve the outcome of patients with high-risk pediatric sarcomas. Vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide are highly effective against pediatric sarcomas...
  47. pmc Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
    Marinus H J van Oers
    Department of Hematology, F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2853-8. 2010
    ..At that time, the median follow-up for the maintenance phase was 33 months. Now, we report the long-term outcome of maintenance treatment, with a median follow-up of 6 years...
  48. ncbi Improving outcomes for patients with diffuse large B-cell lymphoma
    Christopher R Flowers
    Bone Marrow and Stem Cell Transplantation, Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    CA Cancer J Clin 60:393-408. 2010
    ..natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades...
  49. ncbi Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?
    E Groninger
    Division of Paediatric Oncology Haematology, Beatrix Children s Hospital Groningen, Groningen, The Netherlands
    Int J Oncol 21:1339-45. 2002
    b>Vincristine (VCR), a microtubule interfering anti-cancer agent, plays a key role in the treatment of childhood acute lymphoblastic leukaemia (ALL). The route of VCR induced apoptosis in ALL cells is not well defined...
  50. ncbi An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
    J Boye
    Clinic I of Internal Medicine, University Hospital of Cologne, Germany
    Ann Oncol 14:520-35. 2003
    ..diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). The monoclonal antibody is generally well tolerated...
  51. ncbi Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
    Mary Ann Weiser
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1179-85. 2004
    ..during induction chemotherapy for ALL using a regimen comprised of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) and to determine its effect on survival, duration of disease ..
  52. ncbi The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  53. pmc Adipocytes impair leukemia treatment in mice
    James W Behan
    Divisions of Endocrinology, Childrens Hospital Los Angeles, Los Angeles, CA, USA
    Cancer Res 69:7867-74. 2009
    ..Obesity increased relapse after monotherapy with vincristine (P = 0.03) in obese mice injected with syngeneic ALL cells...
  54. ncbi Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
    Paul M Barr
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Am J Hematol 84:484-7. 2009
    ..of cytotoxic agents through modulation of the protein kinase C pathway and is active in combination with vincristine for diffuse large B-cell lymphoma...
  55. ncbi Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
    German Ott
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Blood 116:4916-25. 2010
    ....
  56. ncbi Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma
    D H Kim
    Leukemia 21:2227-30. 2007
  57. ncbi Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
    Lisa M DeAngelis
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:4643-8. 2002
    ..Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCNSL...
  58. ncbi Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    Herve Tilly
    Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
    Blood 102:4284-9. 2003
    ..cyclophosphamide, vindesine, bleomycin, prednisone) with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in previously untreated patients with poor-risk aggressive lymphoma...
  59. ncbi Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  60. ncbi Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
    ..The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy.
  61. pmc Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
    Nathalie Mourad
    INSERM U728, Paris, France
    Blood 111:4463-70. 2008
    ..One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen with intensified courses in half of them...
  62. pmc Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells
    Chiang Siau
    Department of Anesthesia, McGill University, Montreal, Quebec, Canada
    Exp Neurol 201:507-14. 2006
    Experimental painful peripheral neuropathies produced by the chemotherapeutic drugs, paclitaxel and vincristine, are produced by relatively low doses that do not cause axonal degeneration in peripheral nerve...
  63. ncbi Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia
    H R Weng
    The Division of Anesthesiology and Critical Care Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Pain 103:131-8. 2003
    Abnormal sensation and pain are major dose-limiting factors in cancer chemotherapy with vincristine. In this study, we have adapted a model of this condition by using repeated daily intraperitoneal injections of vincristine in rats...
  64. ncbi Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    A Wunderlich
    Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 14:881-93. 2003
    ..intensified variants of the classical 3-weekly CHOP-21 chemotherapy [cyclophosphamide (C), doxorubicin (H), vincristine (O), prednisone (P)] may improve treatment outcome in aggressive lymphoma...
  65. ncbi Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 22:4711-6. 2004
    ..response (DR) data are presented from a multicenter, phase II trial of rituximab/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination therapy in 40 patients with CD20+, B-cell, non-Hodgkin's lymphoma (NHL)...
  66. ncbi LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance
    Miroslav Barancik
    Institute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, PO Box 104, 840 05, Bratislava 45, Slovak Republic
    Eur J Pharm Sci 29:426-34. 2006
    ..We found that LY 294,002, a specific inhibitor of PI3K/Akt kinase pathway, reduced the degree of vincristine resistance in L1210/VCR cells significantly and in a concentration-dependent manner...
  67. ncbi Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group
    Jane L Meza
    Department of Preventive and Societal Medicine, 984350 Nebraska Medical Center, Omaha, NE 68198 4350, USA
    J Clin Oncol 24:3844-51. 2006
    ..The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy...
  68. ncbi Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
    Kai Fu
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 26:4587-94. 2008
    ..However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear...
  69. ncbi Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine
    Karine Thibault
    ESPCI CNRS UMR 7637, Paris, France
    Eur J Pharmacol 600:71-7. 2008
    b>Vincristine is a common anti-cancer therapy administered for the treatment of many types of tumors. Its dose-limiting side effect is the production of peripheral neuropathy, resulting in chronic neuropathic pain in many patients...
  70. pmc A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
    Alison T Stopeck
    University of Arizona Cancer Center, Tucson, AZ, USA
    Blood 120:1210-7. 2012
    S0515 was a phase 2 trial to determine whether the addition of bevacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab (R-CHOP) would improve progression-free survival (PFS) without adding significant ..
  71. ncbi Vincristine induced cranial neuropathy
    Gaurav Dixit
    Department of Medicine, Pt B D Sharma PGIMS, Rohtak 124001
    J Assoc Physicians India 60:56-8. 2012
    Neuropathy is a well known side effect of vincristine, however cranial nerve toxicities are reported less frequently which can involve any cranial nerve in mostly bilateral pattern...
  72. ncbi The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment
    Zu Guang Xia
    Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Ann Hematol 89:171-7. 2010
    ..Furthermore, the use of rituximab alongside classical chemotherapy regimens can improve the outcomes for DLBCL patients who exhibit both GCB and non-GCB subtypes of the disease...
  73. pmc Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
    Jeffrey A Silverman
    Talon Therapeutics Inc, 400 Oyster Point Blvd, Suite 200, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 71:555-64. 2013
    b>Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents...
  74. ncbi Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells
    Hengrui Zhu
    State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, 220 Handan Rd, Shanghai 200433, China
    Eur J Pharmacol 696:43-53. 2012
    ..effect on KB/VCR cells and other cells, while the compound at these concentrations enhanced the cytotoxicity of vincristine (VCR) to KB/VCR cells. H6 showed a significant synergistic effect in combination with VCR...
  75. ncbi Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5490-8. 2009
    ..b>Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR ..
  76. pmc Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria
    E A Roundhill
    Children s Cancer Research Group, Leeds Institute of Molecular Medicine, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Br J Cancer 106:1224-33. 2012
    ..In this study, we describe for the first time the expression of mitochondrial MRP-1 in untreated human normal and cancer cells and tissues...
  77. ncbi Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP
    Dok Hyun Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Eur J Haematol 85:149-57. 2010
    ..The introduction of rituximab to the DLBCL treatment regime has led to alterations in the significance of previous prognostic factors...
  78. ncbi Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines
    D W Zhang
    Cancer Research Laboratories and Department of Pathology, Queen s University, Kingston, Ontario K7L 3N6, Canada
    J Biol Chem 276:13231-9. 2001
    ..This mutation created a protein that conferred resistance to doxorubicin without affecting vincristine resistance, or the ability of mrp1 to transport leukotriene C(4) (LTC(4)) and 17beta-estradiol 17-(beta-d-..
  79. ncbi Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
    T Kivela
    Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4, PL 220, Finland
    Eur J Cancer 39:1115-20. 2003
    ..The dose of bleomycin was 15 mg on days 2 and 5, of vincristine 1 mg/m(2) on days 1 and 4, of lomustine 80 mg on day 1, and of dacarbazine (DTIC) 200 mg/m(2) on days 1-5, ..
  80. ncbi Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Annemiek Broyl
    Department of Haematology, Erasmus MC, Rotterdam, Netherlands
    Lancet Oncol 11:1057-65. 2010
    ..cycle) versus late-onset (after two or three treatment cycles) bortezomib-induced peripheral neuropathy and compared them with those of vincristine-induced peripheral neuropathy during the induction phase of a prospective phase 3 trial.
  81. pmc Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
    Ivana N M Micallef
    Mayo Clinic Rochester, Rochester, MN, USA
    Blood 118:4053-61. 2011
    ..large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy...
  82. ncbi Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group
    William R Friedenberg
    Department of Hematology Oncology, Guthrie Foundation for Education and Research, Sayre, Pennsylvania, USA
    Cancer 106:830-8. 2006
    ..An international randomized control study (Phase III) evaluated the use of vincristine, doxorubicin, and dexamethasone (VAD) with (n = 46) and without (n = 48) valspodar in the treatment of patients ..
  83. ncbi Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer
    Annelies Hartman
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatr Blood Cancer 50:833-7. 2008
    ....
  84. ncbi PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency
    Xiangrong Song
    West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, People s Republic of China
    Int J Pharm 350:320-9. 2008
    PLGA nanoparticles simultaneously loaded with vincristine sulfate (VCR) and verapamil hydrochloride (VRP) were prepared via combining O/W emulsion solvent evaporation and salting-out method...
  85. ncbi Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study
    Nicole M Verrills
    Children s Cancer Institute Australia for Medical Research, Randwick, NSW, Australia
    Proteomics 6:1681-94. 2006
    Intrinsic or acquired resistance to vincristine (VCR), an antimicrotubule agent used in the treatment of childhood acute lymphoblastic leukemia (ALL), is a major clinical problem...
  86. ncbi Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy
    K D Tanner
    Department of Oral and Maxillofacial Surgery, Medicine, and Anatomy, Room C 555, Campus Box 0440, NIH Pain Center, University of California, San Francisco, CA 94143 0440, USA
    Neuroscience 118:809-17. 2003
    ..of mechanical stimulus-evoked action potential trains in nociceptive primary afferents in a rat model of vincristine-induced painful peripheral neuropathy...
  87. ncbi Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter ran
    Nicholas Thatcher
    Medical Research Council Clinical Trials Unit, London NW1 2DA, United Kingdom
    J Clin Oncol 23:8371-9. 2005
    Ifosfamide, carboplatin, etoposide, and vincristine, alone and in combination, are highly active against small-cell lung cancer (SCLC)...
  88. ncbi Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma
    Satu Koivula
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Oncol Rep 25:1183-90. 2011
    ..Together, the results provide an advanced picture of the CD20 mediated signaling of DLBCL cells and may provide new targets in future treatment protocols...
  89. ncbi Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German
    Rudolf Weiss
    Private Practice for Hematology, Oncology and Infectious Diseases, Bremen, Germany
    Cancer 106:1560-8. 2006
    ..ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy ..
  90. ncbi Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery
    Jianian Chen
    School of Pharmacy, Shanghai Jiao Tong University, Dongchuan Road 800, Shanghai 200240, China
    Eur J Pharm Sci 47:430-43. 2012
    ..BF-NPs loaded with vincristine sulfate (VCR) were prepared via the water-oil-water emulsion solvent evaporation method...
  91. ncbi Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice
    Norikazu Kiguchi
    Department of Pharmacology, Wakayama Medical University, 811 1 Kimiidera, Wakayama City, Wakayama 641 0012, Japan
    Neurosci Lett 445:140-3. 2008
    Chronic treatment with vincristine (VCR) causes mechanical allodynia as an adverse effect. We previously reported that peripheral macrophage-derived interleukin-6 played a critical role in VCR-induced allodynia...
  92. ncbi Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis
    Iranzu Gonzalez
    Department of Histology and Pathology, School of Medicine Universidad de Navarra, Pamplona, Spain
    Clin Cancer Res 10:751-61. 2004
    ..The stem cell factor/KIT receptor loop may represent a novel target for molecular-based therapies of Ewing tumor. We analyzed the in vitro impact of KIT blockade by imatinib in Ewing tumor cell lines...
  93. ncbi Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines
    Mariana G Garcia
    Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires, IDEHU CONICET, Argentina
    Leuk Res 29:1425-34. 2005
    ..The modulation of this transcription factor by BAY 11-7082 and the chemotherapeutic agents vincristine and doxorubicin was evaluated...
  94. ncbi Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma
    P S Gill
    Kenneth Norris Jr Comprehensive Cancer Center and Hospital, University of Southern California, School of Medicine, Los Angeles, USA
    J Clin Oncol 14:2353-64. 1996
    To compare the safety and efficacy of liposomal daunorubicin (DaunoXome; NeXstar Pharmaceuticals, Inc, Boulder, CO) with a reference regimen of doxorubicin, bleomycin, and vincristine (ABV) in advanced AIDS-related Kaposi's sarcoma (KS).
  95. ncbi A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
    Leena Gandhi
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 109:924-32. 2007
    ..A Phase II study was designed to evaluate VX-710 in combination with doxorubicin and vincristine in patients with sensitive, recurrent small cell lung cancer (SCLC).
  96. ncbi Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:896-9. 2010
    ..This study suggests that baseline N/L ratio at diagnosis is a simple, inexpensive,standardized prognostic factor to assess clinical outcomes in DLBCL patients treated with R-CHOP...
  97. ncbi Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells
    Hao Zhang
    Beijing Institute of Ophthalmology, Beijing Tong Ren Eye Centre, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China
    Cancer Invest 28:156-65. 2010
    ..Its correlation with chemoresistance of cancer cells has attracted much attention. But how Akt affects vincristine-induced cell death in retinoblastoma is unknown...
  98. ncbi Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model
    James J Lynch
    Neuroscience Research, Global Pharmaceutical Research and Development, Dept R4N5, Abbott Laboratories, Bldg AP9A LL, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pain 110:56-63. 2004
    ..is a common, dose-limiting side effect of cancer chemotherapeutic agents, including the vinca alkaloids such as vincristine. The resulting symptoms, which frequently include moderate to severe pain, can often be disabling...
  99. ncbi Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine
    Farzan Fahrtash
    Department of Pediatrics and Child Health, The University of Sydney, Sydney, New South Wales, Australia
    J Pediatr Hematol Oncol 32:506-10. 2010
    ..To date, definitive treatment for these vascular tumors has had limited success...
  100. ncbi Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia
    J Vela-Ojeda
    Department of Hematology, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Apartado postal 14 878, Código postal 07001, Mexico D F, Mexico
    Ann Hematol 81:362-7. 2002
    ..Four patients were treated with vincristine, melphalan, cyclophosphamide, prednisone, and adriamycin (VMCPA), 12 with vincristine, adriamycin, and ..
  101. ncbi High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma
    Dai Chihara
    Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya, 464 8681, Japan
    Int J Hematol 93:502-8. 2011
    ..03). Multivariate analysis revealed that high SUVmax is a significant poor prognostic factor for both PFS and OS, independent of IPI. We showed the important prognostic value of pretreatment SUVmax of PET scan in DLBCL...

Research Grants64

  1. Developing a prediction model for vincristine-induced peripheral neuropathy
    Jamie L Renbarger; Fiscal Year: 2010
    ..b>Vincristine is active against a wide variety of malignancies and has been shown to substantially improve outcomes...
  2. A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
    Daniela Salvemini; Fiscal Year: 2013
    ..g., paclitaxel), platinum-complex (e.g., oxaliplatin), vinca alkaloids (e.g., vincristine) &proteasome-inhibitor (e.g., bortezomib) classes...
  3. Engineering and Evaluation of Human L-Methionase for Cancer Therapy
    Everett Stone; Fiscal Year: 2013
    ..The utility of these enzymes will be investigated both as monotherapy and in combination therapy with vincristine. PUBLIC HEALTH RELEVANCE: Neuroblastoma is the most common extra-cranial solid tumor of childhood with an ..
  4. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer. ..
  5. Investigating the Role of Adipocytes on Leukemia Relapse
    STEVEN DAVID MITTELMAN; Fiscal Year: 2013
    ..We have found that obese mice with ALL are more likely to relapse after treatment with vincristine, even when it is dosed proportional to body weight...
  6. Synthesis, Biosynthesis, and Structure of Antitumor Agents
    Thomas R Hoye; Fiscal Year: 2013
    ..from camptothecin), mitomycin, mylotarg (from calicheamicin), streptozotocin, taxol (and docetaxel), vincristine, and vinblastine. Many more are in various stages of clinical trial. Newman and Cragg report (J. Nat. Prod...
  7. Enzymes of the Vinca Alkaloids
    Aimee Usera; Fiscal Year: 2010
    ..Catharanthus roseus produces a wealth of biologically active alkaloids including the potent anticancer molecules vincristine and vinblastine and the antihypertension agent ajmalicine. The complex nature of the C...
  8. Development of novel small molecule drugs for the treatment of high risk B-ALL
    CATHY A SWINDLEHURST; Fiscal Year: 2013
    ..a variety of cytotoxic drugs, including glucocorticoids, L-asparaginase, anthracyclines, and vinca alkaloids (vincristine)...
  9. Hepatic OATP Drug Transporters and Chemotherapy Disposition
    RICHARD HSINSHIN HO; Fiscal Year: 2013
    ..of commonly used chemotherapeutic agents known to be dependent on hepatic clearance, including docetaxel, vincristine and doxorubicin...
  10. Microenvironment-Leukemia Communication Through Lectins
    NORA C HEISTERKAMP; Fiscal Year: 2013
    ..gal3+/+ pre-B ALL cells into gal3 -/- and +/+ recipients and comparing homing, proliferation and the effect of vincristine and nilotinib treatment...
  11. Discovering a Novel Immunophilin to Lower the Toxicity of Cancer Therapeutics
    Mitchell W Mutz; Fiscal Year: 2012
    ..the onset of CIPN caused by a wide variety of chemotherapeutics including taxanes, platinum complexes, and vincristine. However, clinical trials to prevent peripheral neuropathy using human NGF have failed due to poor ..
  12. BcL-2 Proteins in Mechanism of Anti-mitotic Drug Action
    Timothy C Chambers; Fiscal Year: 2013
    ..derived from pediatric patients with acute lymphoblastic leukemia to establish the role of CDK1 activation in vincristine sensitivity in a clinically relevant setting...
  13. A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
    MICHAEL JAMES BURKE; Fiscal Year: 2012
    ..Chemotherapy with vincristine, prednisone, PEG-asparaginase and doxorubicin will begin on day 8...
  14. Pharmacogenetic Determinants of Vincristine Toxicity and Response
    Jamie L Renbarger; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Vincristine is active against a wide variety of malignancies and has been shown to substantially improve outcomes...
  15. PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)
    William E Evans; Fiscal Year: 2013
    ..used antileukemic agents, thiopurines and glucocorticoids (with complementary studies of L- asparaginase and vincristine)...
  16. Pharmacogenetics of Cyclophosphamide ADRs in
    Jeannine S McCune; Fiscal Year: 2012
    ..transporters involved in the production and elimination of 4HCY are associated with failure-free survival to vincristine/actinomycin/CY (VAC) in children with newly diagnosed intermediate risk rhabdomyosarcoma...
  17. SELECTIVE ADDUCTOR RECOVERY AFTER LARYNGEAL NERVE INJURY
    Randal C Paniello; Fiscal Year: 2013
    ..In a canine study, it was found that a single dose of vincristine injected into the posterior cricoarytenoid (PCA) muscle resulted in significantly stronger closing force, ..
  18. Advancing Drug Development from Medicinal Plants using Transcriptomics and Metabo
    SARAH E O apos CONNOR; Fiscal Year: 2010
    ..provided by applicant): Medicinal plants produce a wealth of pharmaceutical compounds such as taxol, vincristine, and morphine...
  19. Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
    Steven Dubois; Fiscal Year: 2013
    ..at study entry to one of three 131I-mIBG treatment arms: (1) single agent 131I-mIBG, (2) 131I-mIBG plus vincristine and irinotecan, or (3) 131I-mIBG plus vorinostat...
  20. PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children
    Mary V Relling; Fiscal Year: 2013
    ..antileukemic and toxic effects of glucocorticoids, methotrexate, thiopurines, asparaginase, anthracyclines, and vincristine. The approach is summarized in four major Steps...
  21. Mitigating chemotherapy-induced peripheral neuropathy by augmenting axonal NAD
    Samie R Jaffrey; Fiscal Year: 2013
    ..NAD markedly delays and reduces sensory axon degeneration elicited by vinca alkaloids, such as vinblastine and vincristine, which are commonly used in cancer chemotherapy...
  22. Indiana University Center for Pediatric Pharmacology
    Jamie L Renbarger; Fiscal Year: 2013
    ..I will test the hypothesis that combinations of biomarkers are associated with carefully defined measures of vincristine neurotoxicity and pharmacokinetics in two pediatric patient populations...
  23. Novel Approaches for Antitumor and Antiviral Agents
    Barry M Trost; Fiscal Year: 2013
    ..The aspidosperma type indole alkaloid, kopimaline A reverses multidry resistance in vincristine-resistant KB cells and has not been synthesized previously.
  24. NATIONAL WILMS TUMOR STUDY -5
    Daniel Green; Fiscal Year: 2003
    ..with the addition of doxorubicin (CCSK) and doxorubicin and cycophosphamide (anaplasia) to the combination of vincristine and dactinomycin...
  25. STEREOCONTROLLED SYNTHESIS OF BIOACTIVE ALKALOIDS
    VIRESH RAWAL; Fiscal Year: 2007
    ..first part describes studies directed toward the synthesis of the important anticancer agents vinblastine and vincristine, and their analogs...
  26. C-N Bond-Forming Methodologies for the Synthesis of Small Molecules and Peptides
    JENNIFER LYNN STOCKDILL; Fiscal Year: 2012
    ..This method will be utilized in the synthesis of the leuconicine family of alkaloids, which reverse vincristine resistance in KB cells...
  27. PEDIATRIC ONCOLOGY GROUP
    Stephen Lauer; Fiscal Year: 2002
    ..busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-escalated cyclophosphamide and infusions of peripheral blood-derived progenitor cells in refractory ..
  28. C-N Bond-Forming Methodologies for the Synthesis of Small Molecules and Peptides
    JENNIFER LYNN STOCKDILL; Fiscal Year: 2013
    ..This method will be utilized in the synthesis of the leuconicine family of alkaloids, which reverse vincristine resistance in KB cells...
  29. ASSESSMENT OF GENETIC DAMAGE INDUCED BY CHEMOTHERAPY
    JAN LIANG; Fiscal Year: 1992
    ..These drugs include nitrogen, mustard, vincristine, procarbazine and prednisone (MOPP) and adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)...
  30. Formulation Dependent Help Interactions with Chemothera*
    David Kroll; Fiscal Year: 2005
    ..CYP3A4 metabolizes etoposide as well as vincristine, vinblastine, irinotecan (CPT-11) and tamoxifen...
  31. DEVELOPMENT OF SMALL INTESTINAL EPITHELIUM
    Kwo Yih Yeh; Fiscal Year: 1990
    ..will be determined by autoradiography after H-thymidine injection and by metaphase accumulation rates after vincristine administration...
  32. Antitumor Antimitotics That Reverse Tumor Resistance
    Aleem Gangjee; Fiscal Year: 2010
    ..The Vinca alkaloids vincristine and vinblastine as well as Taxol and the taxanes are antitubulin agents used against a wide variety of tumors ..
  33. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
    ..We will utilize available monkeys from other studies to extend this observation to fractionate irradiations...
  34. Cell Survival Pathways and Inhibitors in Leukemia
    Alan Eastman; Fiscal Year: 2003
    ..Finally, activation of Jun N-terminal kinase (JNK) will be assayed in leukemia patients receiving vincristine therapy, to confirm that this pathway is activated at drug concentrations tolerated by patients...
  35. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..METVAN is much more effective than standard chemotherapeutic agents dexamethasone and vincristine in inducing apoptosis in cancer cells...
  36. CELLULAR CONCOMITANTS OF VINCRISTINE RESISTANCE
    JUNE BIEDLER; Fiscal Year: 1992
    The mechanism whereby cells develop resistance to vincristine and other (natural product) chemotherapeutic agents including actinomycin D and adriamycin are not entirely known...
  37. EFFECT OF TAMOXIFEN ON REVERSING THE MDR PHENOTYPE
    Ellin Berman; Fiscal Year: 1992
    ..leukemia line CEM and the myeloid leukemia cell line HL-60 along with, respectively, their vinblastine and vincristine-resistant sublines CEM-VBL and HL- 60/RV+...
  38. Vindoline and Vinblastine
    Dale L Boger; Fiscal Year: 2013
    ..analogues available for examination, and key insights into the structural features of vinblastine and vincristine integral to their binding to tubulin, inhibition of microtubulin formation, and inhibition of cell mitosis and ..
  39. UNDERSTANDING THE DESIGN OF MOLECULAR MOTORS
    John Murray; Fiscal Year: 2000
    ..motile systems have therapeutic applications in humans: colchicine, used for in gouty arthritis; vincristine, vinblastine, and taxol, used for their anti-mitotic effects against a variety of neoplasms; griseofulvin, an ..
  40. RANDOMIZED CLINICAL TRIAL OF A CAPILLARY CLONING SYSTEM
    Daniel Von Hoff; Fiscal Year: 1990
    ..extensive small cell lung cancer will be randomized to receive treatment with either a standard regimen (vincristine + Adriamycin + cytoxan) or treatment with a capillary cloning choice of drugs (most effective two or three ..
  41. DEVELOPMENT OF AN MDR-1 RESISTANCE-REVERSAL ASSAY
    John Fruehauf; Fiscal Year: 1993
    ..Both verapamil and cyclosporin have been found to sensitize patients to doxorubicin and vincristine. However, use of these reversing agents is associated with systemic toxicity, and not all drug resistant ..
  42. LEUKOCYTE ACTIVATION--INFLUENCE OF THE CYTOSKELETON
    Marilyn Pike; Fiscal Year: 1993
    ..Certain anti-neoplastic agents such as vinblastine and vincristine are thought to exert their effects through disruption of the cytoskeleton...
  43. ANALOGS OF ANTINEOPLASTIC INDOLE ALKALOIDS
    RICHARD SUNDBERG; Fiscal Year: 1991
    ..projects is to synthesize and characterize new analogs at the antineoplastic dimeric indole alkaloids of the vincristine- vinblastine type...
  44. Spinal Galanin and its Receptors in Pain Processing
    Tony Yaksh; Fiscal Year: 2005
    ..states (formalin and carrageenan hyperalgesia), and in post nerve injury pain states (Chung tactile allodynia Vincristine evoked tactile allodynia)...
  45. TOTAL SYNTHESES OF INDOLE ALKALOIDS
    MARTIN KUEHNE; Fiscal Year: 2002
    ..In addition, we extend in this project our initial discovery of vinblastine/vincristine congeners that lack the neurotoxicity of the parent anti-cancer drugs, to establishment of structural ..
  46. B CELL REPERTOIRE OF NORMAL AND AUTOIMMUNE MICE
    Richard Riley; Fiscal Year: 1992
    ..In order to test this hypothesis, we will: A) Use vincristine induced metaphase arrest (stathmokinetic) assays to assess the mitotic activity of B cell precursor cells in ..
  47. PREVENTION OF CHEMOTHERAPY-INDUCED HAIR LOSS
    Joaquin Jimenez; Fiscal Year: 2005
    ..frequently used alopecia-inducing anti-neoplastic agents are cyclophosphamide, adriamycin, etoposide, taxol and vincristine. Alopecia is clearly the most feared side effect of chemotherapy...
  48. INTERGROUP RHABDOMYOSARCOMA STUDY
    Gregory Reaman; Fiscal Year: 2002
    ..of cyclophosphamide vs ifosfamide vs ifosfamide + VP-l6, and (2) rank ordering of induction drug doublets (vincristine/melphalan vs ifosfamide/etoposide vs ifosfamide doxorubicin) and their clinical cross-resistance to VAC therapy...
  49. 2,5 CYCLOHEXADIENONES IN NATURAL PRODUCTS SYNTHESIS
    Mark Wentland; Fiscal Year: 2001
    ..efficient asymmetric synthesis of (-)-vindoline component of the important carcinostatic drugs vinblastine and vincristine will be completed during the next grant period...
  50. IN VITRO ASSAYS FOR METHIONINE-DEPENDENT CHEMOTHERAPY
    HUIYAN GUO; Fiscal Year: 1993
    ..cells by methionine deprivation allows the tumor cells to be selectively killed by antitumor drugs such as vincristine when the cell cycle block is alleviated with methionine...
  51. NOVEL THERAPEUTIC APPROACHES IN HIV-ASSOCIATED LYMPHOMAS
    Thomas Kipps; Fiscal Year: 1993
    ..Newly diagnosed patients will be offered treatment with cyclophosphamide, adriamycin, vincristine, prednisone, and etoposide (CHOPE) with zidovudine to reduce HIV load, and rhG-CSF with rhEPO to attenuate bone ..
  52. CENTRAL & PERIPHERAL EFFECT OF VINBLASTINE & VINCRISTINE
    SHARON COREY; Fiscal Year: 1980
    ..is to study the conditions for inducing, the characteristics, and the mechanisms of vinblastine (VLB) and vincristine (VCR) neurotoxicity on peripheral and central neurons...
  53. PLANT ANTITUMOR AGENTS: ISOLATION AND IDENTIFICATION
    Norman Farnsworth; Fiscal Year: 1991
    ..As exemplified by the frequent administration of vincristine, chemical agents demonstrating a high degree of clinical efficacy occur naturally in plants...
  54. NOVEL MITOTIC CHECKPOINT GENE
    Thanos Halazonetis; Fiscal Year: 2005
    ..Indeed, many of the agents that are effective in cancer therapy, such as taxol, vincristine and others, induce mitotic stress...
  55. CORRELATIONS OF NEW AND OLD CELL KINETIC PARAMETERS
    Claudio Nicolini; Fiscal Year: 1980
    ..cytometry determine effects of other DNA antimetabolites (such as hydroxyurea) and antimitotic poisons (such as vincristine) on: a) the cell kinetics and the progression of cells through the cycle, b) chromatin organization in situ, c) ..
  56. Hemangioma Research Workshop
    Ilona Frieden; Fiscal Year: 2005
    ..Other treatments, such as alfa-interferon and vincristine can be effective but have potentially serious side- effects...
  57. Total Synthesis of Kopsimaline A
    Timothy J Barker; Fiscal Year: 2012
    ..Kopsimaline A has been found to be effective at reversing multidrug resistance in vincristine-resistant human cancer KB cells...
  58. Natural Product Leads for Drug Development
    KATHLYN PARKER; Fiscal Year: 2009
    ..SNF4435C is also active in vivo, enhancing the efficacy of vincristine treatment in mice that carry vincristine-resistant P388 leukemia...
  59. BIOSYNTHESIS OF THE ANTITUMOR ALKALOIDS OF CATHARANTHUS
    Alastair Scott; Fiscal Year: 1991
    ..transformations from tryptophan and secologanin up to the complex dimeric oncolytic alkaloids vinblastine and vincristine will be examined...
  60. IDENTIFYING INHIBITORS OF THE APC/C USING YEAST MUTANTS
    Daniel Burke; Fiscal Year: 2007
    ..A number of natural products, such as taxol, vinblastine and vincristine are effective against a broad spectrum of tumors when used individually or in combination therapy...
  61. The Apoptotic Role of MEKK1 in Cancer Chemotherapy
    Genhong Cheng; Fiscal Year: 2007
    ..Microtubule disruption agents such as vinblastine, vincristine, and paclitaxel represent a growing family of anti-cancer drugs...
  62. ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
    Alan Sartorelli; Fiscal Year: 2005
    ..in protecting normal tissue from several anticancer agents, particularly stressing their relationships to vincristine and methotrexate, including their impact on the metabolism and pharmacokinetic disposition of these drugs; (b) ..
  63. Mitotic Checkpoint & Genomic Stability in Ovarian Cancer
    Dong Yan Jin; Fiscal Year: 2006
    ..cancer; and (d) study the anti-proliferative mechanisms of mitotic checkpoint-targeting drugs such as taxol and vincristine using ovarian cancer as a model...
  64. IDENTIFYING INHIBITORS OF THE APC/C USING YEAST MUTANTS
    Daniel Burke; Fiscal Year: 2001
    ..Drugs such as taxo1, vinb1astine and vincristine are effective against certain type of tumors and have an increased spectrum of efficiency when used in ..